/ April 20, 2021 /
Baebies, a growth-stage company developing innovative products to enable early disease detection and comprehensive diagnosis, announced today that CARB-X has awarded the company up to $11.6 million in non-dilutive funding. This funding will support the development of a near-patient and rapid diagnostic platform for sepsis - specially focused on addressing the unique needs of neonatal and pediatric populations.
The CARB-X award consists of $3.9 million in initial funding with up to $7.7 million of milestone-based funding. CARB-X, a global non-profit partnership, provides funding and support for projects that target drug-resistant bacteria deemed Serious or Urgent on the U.S. Centers for Disease Control and Prevention (CDC) Antibiotic Resistant Threats list or Critical or High on the World Health Organization s Priority Bacterial Pathogens list.
Baebies Awarded up to $11 6 Million from CARB-X for the Development of a Diagnostic Platform with Rapid Results for Sepsis phoenixherald.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from phoenixherald.com Daily Mail and Mail on Sunday newspapers.
GARDP welcomes additional funding from UK to develop new treatment for gonorrhoea
The UK government has announced an additional £1.5 million of funding to develop a new treatment for gonorrhoea.
From:
12 February 2021
This investment, on top of £3.5 million committed in 2019, will support the Global Antibiotic Research and Development Partnership (
GARDP) in the development and availability of zoliflodacin, a novel antibiotic, which is currently being assessed as part of a global phase 3 trial for safety and effectiveness as a treatment for gonorrhoea.
This new antibiotic has the potential to treat drug resistant gonorrhoea and is one of the few antibiotics in development specifically for the disease, an important consideration to ensure the treatment remains effective for generations to come.